# Intelligencia AI

> Intelligencia AI is a New York-based artificial intelligence company that helps pharmaceutical and biotech organizations predict the probability of technical and regulatory success (PTRS) for drug candidates. Its patented SaaS platform harmonizes more than 1.5 billion clinical and biological data points to score how likely a drug is to advance through clinical phases and win regulatory approval, with reported prospective accuracy above 80%. The company gives R&D, business development, and portfolio teams transparent, explainable AI to de-risk investment decisions in drug development.

- **Founded:** 2017
- **Headquarters:** New York, United States
- **Founders:** Dimitrios Skaltsas (Co-Founder & CEO), Vangelis Vergetis (Co-Founder)
- **Team size:** ~110 employees
- **Products:** Portfolio Optimizer, Clinical Development Insights, Data as a Subscription, Custom Insights
- **Notable:** Named to Forbes' list of AI companies to watch (2021), Built a patented AI platform for probability of technical and regulatory success, Reports 80%+ prospective and 91% retrospective accuracy on forecasting asset success

## Products & services

- **Portfolio Optimizer** — A patented SaaS platform delivering on-demand, AI-powered PTRS (probability of technical and regulatory success) insights on drug assets, indications, and portfolios, built on proprietary harmonized data.
- **Clinical Development Insights** — AI-driven analytics that assess and de-risk individual clinical programs across all phases of development, with explainability into the factors driving each prediction.
- **Data as a Subscription** — Access to Intelligencia AI's harmonized, curated dataset of 1.5 billion+ clinical and biological data points as a subscription service.
- **Custom Insights** — Bespoke analytical engagements applying the platform and data to a client's specific therapeutic areas and strategic questions.

## Achievements

- Named to Forbes' list of AI companies to watch (2021)
- Built a patented AI platform for probability of technical and regulatory success
- Reports 80%+ prospective and 91% retrospective accuracy on forecasting asset success
- Harmonized more than 1.5 billion clinical and biological data points
- Secured exclusive partnership with global professional-services firm ZS

## Latest updates

- **2025-07** — Coverage in Nature Biotechnology ('Clinical trials gain intelligence') highlighting AI-driven probability-of-success approaches in the industry.
- **2021-08** — Closed $12M Series A led by MTIP and announced exclusive partnership with ZS.

## Links

- Website: https://intelligencia.ai
- LinkedIn: http://www.linkedin.com/company/intelligencia-ai

---

Profile page: https://yespress.io/intelligencia-ai
Published by YesPress — https://yespress.io
Last updated: 2026-07-20